Literature DB >> 18521368

Management of advanced adult soft tissue sarcoma.

Vivien H C Bramwell1.   

Abstract

Entities:  

Year:  2003        PMID： 18521368      PMCID： PMC2395519          DOI： 10.1080/13577140310001607266

Source DB:  PubMed          Journal:  Sarcoma        ISSN： 1357-714X


× No keyword cloud information.
  90 in total

Review 1.  Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.

Authors:  G D Demetri; A D Elias
Journal:  Hematol Oncol Clin North Am       Date:  1995-08       Impact factor: 3.722

2.  Needed: qualitative improvement in antisarcoma therapy.

Authors:  J H Edmonson
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544

3.  Sarcoma metastatic to the brain: results of surgical treatment.

Authors:  R K Bindal; R E Sawaya; M E Leavens; S H Taylor; V F Guinee
Journal:  Neurosurgery       Date:  1994-08       Impact factor: 4.654

4.  High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.

Authors:  A Le Cesne; E Antoine; M Spielmann; T Le Chevalier; E Brain; C Toussaint; N Janin; L Kayitalire; F Fontaine; J Genin
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544

5.  Synovial sarcoma. Uniform response of metastases to high dose ifosfamide.

Authors:  G Rosen; C Forscher; S Lowenbraun; F Eilber; J Eckardt; C Holmes; Y S Fu
Journal:  Cancer       Date:  1994-05-15       Impact factor: 6.860

6.  Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine.

Authors:  G M Mavligit; A A Zukwiski; L M Ellis; V P Chuang; S Wallace
Journal:  Cancer       Date:  1995-04-15       Impact factor: 6.860

7.  Effects of amphotericin B on combination chemotherapy of metastatic sarcomas.

Authors:  C A Presant; A A Bartolucci; S Lowenbraun
Journal:  Cancer       Date:  1984-01-15       Impact factor: 6.860

8.  Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.

Authors:  J H Edmonson; L M Ryan; R H Blum; J S Brooks; M Shiraki; S Frytak; D R Parkinson
Journal:  J Clin Oncol       Date:  1993-07       Impact factor: 44.544

9.  Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

Authors:  A Santoro; T Tursz; H Mouridsen; J Verweij; W Steward; R Somers; J Buesa; P Casali; D Spooner; E Rankin
Journal:  J Clin Oncol       Date:  1995-07       Impact factor: 44.544

Review 10.  Pulmonary metastasectomy for soft tissue sarcomas: is it justified?

Authors:  D B Frost
Journal:  J Surg Oncol       Date:  1995-06       Impact factor: 3.454
View more
  2 in total

1.  A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma.

Authors:  S Thomas; R Aggarwal; T Jahan; C Ryan; T Troung; A M Cripps; P Raha; K T Thurn; S Chen; J A Grabowsky; J Park; J Hwang; A Daud; P N Munster
Journal:  Ann Oncol       Date:  2016-02-21       Impact factor: 32.976

2.  Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas.

Authors:  Shriram V Nath; H Miles Prince; Peter Fm Choong; Guy C Toner
Journal:  Int Semin Surg Oncol       Date:  2005-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.